About 88 percent of patients who took Tagrisso were alive at five years, and the placebo had a 78 percent survival rate, according to a June 2 news release. Those in the placebo group who recurred with metastatic disease had the chance to take Tagrisso as a subsequent treatment.
The participants had early-stage, epidermal growth factor receptor-mutated non-small cell lung cancer. A median overall survival rate was not reached within months but was achieved after five years.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
